Browsing by Author Hong, Zhenya
Showing results 1 to 2 of 2
Issue Date | Title | Author(s) |
23-Nov-2021 | Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) | Qian, Jiang; Shi, Dayu; Li, Zongru; Hou, Yue; Hu, Yu; Li, Weiming; Liu, Xiaoli; Xu, Na; Song, Yongping; Zhang, Gongli; Meng, Li; Hong, Zhenya; Liu, Bingcheng; Li, Yan; Chen, Suning; Xue, Mengxing; Zhu, Huanling; Li, He; Du, Xin; Lou, Jin; Zhang, Xiaohan; Liang, Yang; Dai, Yujun; Chen, Zi; Niu, Qian; Men, Lichuang; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
15-Nov-2022 | Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation | Jiang, Qian; Li, Zongru; Hou, Yue; Hu, Yu; Li, Weiming; Liu, Xiaoli; Xu, Na; Zhang, Yanli; Song, Yongping; Meng, Li; Hong, Zhenya; Liu, Bingcheng; Li, Yan; Chen, Suning; Xue, Mengxing; Zhu, Huanling; Li, He; Du, Xin; Lou, Jin; Zhang, Xiaohan; Liang, Yang; Dai, Yu-Jun; Chen, Zi; Niu, Qian; Men, Lichuang; Yang, Dajun; Zhai, Yifan; Huang, Xiao-Jun |